Season’s greetings and best wishes for the new year
The resistance of certain bacteria to antibiotics is currently a major health problem. In a publication in the prestigious scientific journal Cell, researchers lead by Jean-François Collet, Investigator WELBIO at UCL, describe how RcsF is involved in bacterial defence mechanisms against antibiotics.
The group of Pierre Vanderhaeghen, Investigator WELBIO at ULB, identifies a key factor that can suppress medulloblastoma, the most frequent child brain tumour. This research, published in the journal Cancer Cell, opens new perspectives on the diagnosis and treatment of these brain tumors
In a study published in Nature Communications, the research team of Patrice D. Cani, WELBIO investigator at UCL, has identified a novel mechanism involved in the development of obesity and type 2 diabetes following a high-fat diet feeding. This work identifies a novel therapeutic target for the treatment of obesity and type 2 diabetes.
In a study published in Nature Communications, the group of Alain Chariot, WELBIO investigator at GIGA, Université de Liège, Belgium, identified a new role for the protein KIAA1199 in cervical cancer development resulting from HPV infection.
This short video (FR) that describes WELBIO’s missions was created in the context of the « Minute Marshall » which highlights the projects supported by the Marshall Plan 2. green with the objective of promoting the economic expansion of Wallonia.
Etienne Pays, WELBIO investigator at the IBMM, Université Libre de Bruxelles, received this prestigious prize in recognition for his numerous ground breaking discoveries on trypanosomal diseases, from the understanding of antigenic variation to the description of innate immunity protecting humans against infection by some African trypanosomes as well as the different mechanisms of resistance of pathogenic trypanosomes to this immunity.
In a study published in the Proceedings of the National Academy of Sciences USA, researchers lead by André Goffient, WELBIO investigator at the Université catholique de Louvain (UCL), Belgium, report on the essential roles played by the membrane proteins Celsr2, Celsr3 and Fzd3 during anterior brain development.
In a review published in Nature Reviews Microbiology, Professor Etienne Pays, WELBIO investigator at the IBMM, Université Libre de Bruxelles, and colleagues summarize current knowledge on the unique relationship between humans and African trypanosomes, the parasites responsible for sleeping sickness.
In a new study published in Nature, researchers led by Cédric Blanpain, WELBIO investigator at the IRIBHM, Université libre de Bruxelles, Belgium, demonstrate an essential role for the transcription factor Sox2 in regulating tumour initiation and cancer stem cell functions in skin squamous cell carcinoma.
WELBIO is now counting 23 research programmes of excellence, established financial resources to initiate the valorisation of results generated by its research programmes, and consolidated its administrative structure.
In a study published in Cell Reports, the group lead by Alain Chariot, WELBIO investigator at GIGA, Université de Liège, Belgium, describes the role of IKKα kinase in intestinal tumorigenesis.
In a study published in Cell Reports, the group of Laurent Nguyen, WELBIO investigator at GIGA-Neurosciences, Université de Liège, Belgium, has discovered a new molecular mechanism that controls neuronal migration in the developing cerebral cortex. These results uncovered two microRNAs that regulate the expression of a gene implied in projection neuron polarisation and migration
In a study published in Journal of Molecular Endocrinology, researchers led by Stéphane Schurmans, WELBIO investigator at GIGA, Université de Liège, report on the role played by the molecular motor KIF3A in thyroid function. The excellence in endocrine research of this publication is recognized by the 2013 Society for Endocrinology journal awards.
In a study published in Cell Death & Differentiation, the group of Alain Chariot, WELBIO investigator at GIGA, Université de Liège, Belgium, identified that MDM2, overexpressed in tumor cells, can degrade not only p53 but also HPIP, a protein essential to modulate the estrogen-response in mammary epithelial cells.